Product Images Fesoterodine Fumarate

This is a medication with NDC code 51407-661-30. It contains extended-release tablets that come in a bottle of 30 tablets. Each tablet is film-coated and contains 4 mg of fesoterodine fumarate. The medication should be stored at room temperature, protected from moisture, and kept out of reach of children. Patients should not chew, divide, or crush the tablets, and the appropriate dosage should be determined by a healthcare professional. The patient information can be found on https/igsms.usi and must be dispensed by the pharmacist. Manufactured by Dr. Reddy’s Laboratories Limited and marketed by GSMS, Incorporated. Last revised in July 2022.*

NDC 51407-862-30 is a medication called Ghicccomiamerosaorcane Fumarate. It is available in extended-release tablets containing 8mg of Fumarate. Dosage instructions can be found in the accompanying Prescribing Information. The medication should be swallowed whole and not chewed, crushed or divided. It should be kept protected from moisture at 20° - 25°C (68° - 77°F). The medication should be kept out of reach of children. Patient information can be printed at https://gsms.us/. This medication is manufactured by Dr. Reddy's Laboratories Limited and marketed by GSMS, Incorporated in Camarillo, CA 93012 USA. This information is only for the pharmacist for dispensing and does not include a useful description for the general public.*

This is a description of a study that measured the change in the number of micturitions (urinations) per 24 hours in participants taking a medication called Fesoterodine fumarate 4mg. The study involved 279 participants and lasted for 12 weeks. The figure provided shows the change in the number of micturitions over time.*

The text is describing a chart or a graph displaying the change in urge incontinence episodes per day over the course of 12 weeks. The chart includes data from a study with a sample size of 211 individuals. The text mentions different time intervals at which data was collected (0, 2, 8, and 12 weeks).*

The text describes a figure that shows the change in urge incontinence episodes per 24 hours over 12 weeks in a study involving 205 participants. The data is presented in a graph and includes data points for weeks 0, 2, 8, and 12. The mean change from baseline is specified.*